Cambrex Adds Large Scale Manufacturing Capacity at Its Charles City, Iowa Facility

East Rutherford, NJ – October 23, 2017 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced the completion of an expansion to its large scale production capacity at its Charles City, Iowa plant. The investment included the installation of 1,000 and 4,000 gallon glass lined reactors in addition to ancillary equipment.

The new reactors have been installed in the 7,500 sq. ft. multi-purpose manufacturing facility which opened at the site in 2016. This brings the cGMP reactor capacity in this newest facility to 23,000 gallons, with the total capacity at the Charles City facility now approximately 107,000 gallons.

“Cambrex continues to experience strong demand for large scale small molecule API manufacturing,” commented Shawn Cavanagh, COO of Cambrex. He added, “Charles City is a key strategic site within our global manufacturing network and this additional capacity enables us to take on new customer projects, as well as offering the flexibility for projects to be transferred in from other Cambrex sites as needed.”

This latest expansion follows the announcement of the construction of a $24M, 4,500 sq. ft. highly potent API (HPAPI) manufacturing facility at the Charles City facility, which is due to open in 2019.

Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The facility is one of only a limited number authorized by the US DEA to import narcotic raw materials at commercial scale.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit

Contact: Alex Maw

Director, Marketing and Communications

Tel: +44 7803 443 155


Posted by Hannah McLachlan